Purpose: Meta-[F-18]fluorobenzylguanidine ([F-18]mFBG) is a positron emission tomography (PET) radiotracer that allows for fast and high-resolution imaging of tumours expressing the norepinephrine... Show morePurpose: Meta-[F-18]fluorobenzylguanidine ([F-18]mFBG) is a positron emission tomography (PET) radiotracer that allows for fast and high-resolution imaging of tumours expressing the norepinephrine transporter. This pilot study investigates the feasibility of [F-18]mFBG PET-CT for imaging in neuroblastoma. Methods: In a prospective, single-centre study, we recruited children with neuroblastoma, referred for meta-[I-123]iodobenzylguanidine ([I-123]mIBG) scanning, consisting of total body planar scintigraphy in combination with single-photon emission computed tomography-CT (SPECT-CT). Within two weeks of [I-123]mIBG scanning, total body PET-CTs were performed at 1 h and 2 h after injection of [F-18]mFBG (2 MBq/kg). Detected tumour localisations on scan pairs were compared. Soft tissue disease was quantified by number of lesions and skeletal disease by SIOPEN score. Results: Twenty paired [I-123]mIBG and [F-18]mFBG scans were performed in 14 patients (median age 4.9 years, n = 13 stage 4 disease and n = 1 stage 4S). [F-18]mFBG injection was well tolerated and no related adverse events occurred in any of the patients. Mean scan time for [F-18]mFBG PET-CT (9.0 min, SD 1.9) was significantly shorter than for [I-123]mIBG scanning (84.5 min, SD 10.5), p < 0.01. Most tumour localisations were detected on the 1 h versus 2 h post-injection [F-18]mFBG PET-CT. Compared to [I-123]mIBG scanning, [F-18]mFBG PET-CT detected a higher, equal, and lower number of soft tissue lesions in 40%, 55%, and 5% of scan pairs, respectively, and a higher, equal, and lower SIOPEN score in 55%, 30%, and 15% of scan pairs, respectively. On average, two more soft tissue lesions and a 6-point higher SIOPEN score were detected per patient on [F-18]mFBG PET-CT compared to [I-123]mIBG scanning. Conclusion: Results of this study demonstrate feasibility of [F-18]mFBG PET-CT for neuroblastoma imaging. More neuroblastoma localisations were detected on [F-18]mFBG PET-CT compared to [I-123]mIBG scanning. [F-18]mFBG PET-CT shows promise for future staging and response assessment in neuroblastoma. Show less
Vargas, C.S.; Bauwens, M.; Pooters, I.N.A.; Pomme, S.; Peters, S.M.B.; Segbers, M.; ... ; Wierts, R. 2020
BackgroundPersonalized molecular radiotherapy based on theragnostics requires accurate quantification of the amount of radiopharmaceutical activity administered to patients both in diagnostic and... Show moreBackgroundPersonalized molecular radiotherapy based on theragnostics requires accurate quantification of the amount of radiopharmaceutical activity administered to patients both in diagnostic and therapeutic applications. This international multi-center study aims to investigate the clinical measurement accuracy of radionuclide calibrators for 7 radionuclides used in theragnostics: Tc-99m, In-111, I-123, I-124, I-131, Lu-177, and Y-90.MethodsIn total, 32 radionuclide calibrators from 8 hospitals located in the Netherlands, Belgium, and Germany were tested. For each radionuclide, a set of four samples comprising two clinical containers (10-mL glass vial and 3-mL syringe) with two filling volumes were measured. The reference value of each sample was determined by two certified radioactivity calibration centers (SCK CEN and JRC) using two secondary standard ionization chambers. The deviation in measured activity with respect to the reference value was determined for each radionuclide and each measurement geometry. In addition, the combined systematic deviation of activity measurements in a theragnostic setting was evaluated for 5 clinically relevant theragnostic pairs: I-131/I-123, I-131/I-124, Lu-177/In-111, Y-90/Tc-99m, and Y-90/In-111.ResultsFor Tc-99m, I-131, and Lu-177, a small minority of measurements were not within 5% range from the reference activity (percentage of measurements not within range: Tc-99m, 6%; I-131, 14%; Lu-177, 24%) and almost none were outside +/- 10% range. However, for In-111, I-123, I-124, and Y-90, more than half of all measurements were not accurate within +/- 5% range (In-111, 51%; I-123, 83%; I-124, 63%; Y-90, 61%) and not all were within +/- 10% margin (In-111, 22%; I-123, 35%; I-124, 15%; Y-90, 25%). A large variability in measurement accuracy was observed between radionuclide calibrator systems, type of sample container (vial vs syringe), and source-geometry calibration/correction settings used. Consequently, we observed large combined deviations (percentage deviation > +/- 10%) for the investigated theragnostic pairs, in particular for Y-90/In-111, I-131/I-123, and Y-90/Tc-99m.Conclusions Our study shows that substantial over- or underestimation of therapeutic patient doses is likely to occur in a theragnostic setting due to errors in the assessment of radioactivity with radionuclide calibrators. These findings underline the importance of thorough validation of radionuclide calibrator systems for each clinically relevant radionuclide and sample geometry. Show less
Peters, S.M.B.; Viol, S.L.M.; Werf, N.R. van der; Jong, N. de; Velden, F.H.P. van; Meeuwis, A.; ... ; Segbers, M. 2020
Background Quantitative SPECT imaging in targeted radionuclide therapy with lutetium-177 holds great potential for individualized treatment based on dose assessment. The establishment of dose... Show moreBackground Quantitative SPECT imaging in targeted radionuclide therapy with lutetium-177 holds great potential for individualized treatment based on dose assessment. The establishment of dose-effect relations requires a standardized method for SPECT quantification. The purpose of this multi-center study is to evaluate quantitative accuracy and inter-system variations of different SPECT/CT systems with corresponding commercially available quantitative reconstruction algorithms. This is an important step towards a vendor-independent standard for quantitative lutetium-177 SPECT. Methods Four state-of-the-art SPECT/CT systems were included: Discovery (TM) NM/CT 670Pro (GE Healthcare), Symbia Intevo (TM), and two Symbia (TM) T16 (Siemens Healthineers). Quantitative accuracy and inter-system variations were evaluated by repeatedly scanning a cylindrical phantom with 6 spherical inserts (0.5 - 113 ml). A sphere-to-background activity concentration ratio of 10:1 was used. Acquisition settings were standardized: medium energy collimator, body contour trajectory, photon energy window of 208 keV (+/- 10%), adjacent 20% lower scatter window, 2 x 64 projections, 128 x 128 matrix size, and 40 s projection time. Reconstructions were performed using GE Evolution with Q.Metrix (TM), Siemens xSPECT Quant (TM), Siemens Broad Quantification (TM) or Siemens Flash3D (TM) algorithms using vendor recommended settings. In addition, projection data were reconstructed using Hermes SUV SPECT (TM) with standardized reconstruction settings to obtain a vendor-neutral quantitative reconstruction for all systems. Volumes of interest (VOI) for the spheres were obtained by applying a 50% threshold of the sphere maximum voxel value corrected for background activity. For each sphere, the mean and maximum recovery coefficient (RCmean and RCmax) of three repeated measurements was calculated, defined as the imaged activity concentration divided by the actual activity concentration. Inter-system variations were defined as the range of RC over all systems. Results RC decreased with decreasing sphere volume. Inter-system variations with vendor-specific reconstructions were between 0.06 and 0.41 for RCmean depending on sphere size (maximum 118% quantification difference), and improved to 0.02-0.19 with vendor-neutral reconstructions (maximum 38% quantification difference). Conclusion This study shows that eliminating sources of possible variation drastically reduces inter-system variation in quantification. This means that absolute SPECT quantification for Lu-177 is feasible in a multi-center and multi-vendor setting; however, close agreement between vendors and sites is key for multi-center dosimetry and quantitative biomarker studies. Show less
